US gastroenterologists' familiarity and experience with Entyvio has increased

A majority of surveyed US gastroenterologists are highly familiar with Entyvio (vedolizumab), with 62% reporting they have prescribed Entyvio, produced by Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502), to at least one of their ulcerative colitis (UC) or Crohn’s disease (CD) patients.

According to market research group Decision Resources, many surveyed and interviewed physicians cite Entyvio's new mechanism of action and its efficacy as a perceived advantage as lack or loss of response in patients using anti-TNF agents is a substantial concern. Although clinical data suggest weaker efficacy in CD than UC, and that the theoretical risk of PML is still a concern for many surveyed physicians, a majority of gastroenterologists indicate a high level of willingness to prescribe Entyvio for both UC and CD.

Other key findings from the LaunchTrends report titled "Entyvio Wave 3 (US)"